Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily
- 1 May 1992
- journal article
- clinical trial
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 15 (4) , 111-117
- https://doi.org/10.1016/0732-8893(92)90137-i
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Macrolide pharmacokinetics and dose scheduling of roxithromycinDiagnostic Microbiology and Infectious Disease, 1992
- Clinical Pharmacokinetic Properties of the Macrolide AntibioticsClinical Pharmacokinetics, 1989
- Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibioticAntimicrobial Agents and Chemotherapy, 1987
- Effect of roxithromycin on acute toxoplasmosis in miceAntimicrobial Agents and Chemotherapy, 1987
- Roxithromycin: a pharmacokinetic review of a macrolideJournal of Antimicrobial Chemotherapy, 1987
- A review of the in-vitro activity of roxithromycin against genital pathogensJournal of Antimicrobial Chemotherapy, 1987
- Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: an overviewJournal of Antimicrobial Chemotherapy, 1987
- Roxithromycin in the therapy of Streptococcus pyogenes throat infectionsJournal of Antimicrobial Chemotherapy, 1987
- In-vitro activity of roxithromycin against respiratory and skin pathogensJournal of Antimicrobial Chemotherapy, 1987
- In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984